Procter & Gamble Health profit and loss

Latest FY27

Revenue: ₹364cr+7.4% on FY26
EBITDA: ₹99.6cr+10.3% on FY26
Net profit: ₹96.2cr+45.3% on FY26
EPS: ₹57.92+45.3% on FY26

₹ crore except per share

Tap a line for its trend	FY27Jun 2026	FY26Jun 2025	FY25Jun 2024	FY24Jun 2023	FY23 and earlierAlpha Plus

Expenses
	364	339	1,151	1,230	FY23 and earlierEvery year the company has filed comes with Alpha Plus.
	3.9	4.0	15.6	18.4
	368	343	1,167	1,248
	80.3	59.5	290	319
	24.6	24.3	39.5	39.8
	−8.7	10.1	0.9	2.9
	60.4	56.0	215	206
	0.1	0.1	0.7	0.8
	6.0	5.4	27.4	27.4
	108	98.4	300	338
	270	254	873	934
	99.6	90.3	306	324
	93.6	84.9	279	297
Profit
	97.3	88.8	294	314
	31.8	0.0	−20.2	0.0
	129	88.8	273	314
	31.0	22.9	80.9	89.8
	1.9	−0.3	−8.6	−5.1
	33.0	22.6	72.3	84.7
	96.2	66.2	201	229
	96.2	66.2	201	229
	0.3	−0.7	0.7	−1.8
	96.5	65.5	202	228
Per share
	₹57.92	₹39.87	₹121.07	₹138.23
	₹57.92	₹39.87	₹121.07	₹138.23
Other comprehensive income — detail
	0.3	−0.7	—	—
	0.4	−0.9	0.9	−2.5
	0.1	−0.2	—	—
	—	—	0.2	−0.6
Per share — as-filed variants
	₹57.92	₹39.87	₹121.07	₹138.23
	₹57.92	₹39.87	₹121.07	₹138.23
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	267	245	821	868
	73.5%	72.3%	71.3%	70.6%
Adjusted (ex-exceptional items) — derived
	97.3	88.8	294	314
	31.8	0.0	−20.2	0.0
	72.5	66.2	216	229
	₹43.66	₹39.87	₹130.01	₹138.23

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PGHL₹5,399.00

Procter & Gamble Health Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSANOFICONR SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDC ASTRAZENMcap ₹8,962 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 30/06/2023	FY25 30/06/2024	FY26 30/06/2025	FY27 30/06/2026
Revenue from Operations	1,229.6	1,151.3	338.7	363.7
Other Income	18.4	15.6	4.0	3.9
Total Income	1,248.0	1,166.9	342.8	367.6
Expenses
+ Cost of Materials Consumed	319.2	290.2	59.5	80.3
+ Purchases of Stock-in-Trade	39.8	39.5	24.3	24.6
+ Changes in Inventories	2.9	0.9	10.1	-8.7
+ Employee Benefit Expense	206.2	215.2	56.0	60.4
+ Finance Costs	0.8	0.7	0.1	0.1
+ Depreciation & Amortisation	27.4	27.4	5.4	6.0
+ Other Expenses	337.7	299.5	98.4	107.5
Total Expenses	933.8	873.4	254.0	270.3
EBITDA	324.0	306.0	90.3	99.6
EBIT	296.6	278.6	84.9	93.6
Profit
PBT before Exceptional Items	314.2	293.5	88.8	97.3
+ Exceptional Items	0.0	-20.2	0.0	31.8
Pretax Income	314.2	273.3	88.8	129.1
+ Current Tax	89.8	80.9	22.9	31.0
+ Deferred Tax	-5.1	-8.6	-0.3	1.9
Tax Expense	84.7	72.3	22.6	33.0
Net Income	229.5	201.0	66.2	96.2
+ Net Income — Continuing Ops	229.5	201.0	66.2	96.2
+ Other Comprehensive Income	-1.8	0.7	-0.7	0.3
Total Comprehensive Income	227.6	201.7	65.5	96.5
Per Share
Basic EPS	138.23	121.07	39.87	57.92
Diluted EPS	138.23	121.07	39.87	57.92
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.7	0.3
+ Items NOT to be Reclassified to P&L	-2.5	0.9	-0.9	0.4
+ Tax on Items NOT to be Reclassified	—	—	-0.2	0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.6	0.2	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	138.23	121.07	39.87	57.92
Diluted EPS — Continuing Operations	138.23	121.07	39.87	57.92
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	867.8	820.7	244.8	267.5
Gross Margin %	70.57	71.29	72.25	73.54
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	314.2	293.5	88.8	97.3
− Exceptional Items (reconciliation)	0.0	-20.2	0.0	31.8
Net Income Adj (tax-effected)	229.5	215.8	66.2	72.5
EPS Adj	138.23	130.01	39.87	43.66
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00
Paid Up Equity Capital	16.6	16.6	16.6	16.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.